Well I hope so- the name is BIO HEART, as it seemed that heart applications was always the end game, and of course FDA approval if in any way possible- the big, huge end game payoff.
Just see what I'm saying - they seem to sure be getting off (use an old golfer term) "in the weeds a bit"?
I just hope Mirror is not stalled out. 10-K is the big, next update- so we'll see. Just seems like relatively few resources, chasing more and more of a scatter-shot approach. Old approach seemed more intense focus, stay on target and go for the goal line in the cardiac, FDA "trial" arena?
Just throws me off a bit, that's all.
News 
Market Data 
Discover 
